Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights

References

• Radolf JD, Caimano MJ, Stevenson B, et al. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat Rev Microbiol. 2012;10(2):87–99.
   PubMed Web of Science ®Google Scholar
• Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090.
   PubMed Web of Science ®Google Scholar
• Sykes RA, Makiello P. An estimate of Lyme borreliosis incidence in Western Europedagger. J Public Health (Oxf). 2017;39(1):74–81.
   PubMed Web of Science ®Google Scholar
• Kugeler KJ, Schwartz AM, Delorey MJ, et al. Estimating the frequency of Lyme disease diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021;27(2):616–619.
   PubMed Web of Science ®Google Scholar
• Strle K, Jones KL, Drouin EE, et al. Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease. Am J Pathol. 2011;178(6):2726–2739.
   PubMed Web of Science ®Google Scholar
• Dykhuizen DE, Brisson D, Sandigursky S, et al. The propensity of different Borrelia burgdorferi sensu stricto genotypes to cause disseminated infections in humans. Am J Trop Med Hyg. 2008;78(5):806–810.
   PubMed Web of Science ®Google Scholar
• Steere AC, Strle K, and Drouin EE. Infection and autoimmunity. Yehuda Shoenfeld NA-L, Noel RR, eds. London, UK: Academic Press: 2015.
   Google Scholar
• Wolcott KA, Margos G, Fingerle V, et al. Host association of Borrelia burgdorferi sensu lato: a review. Ticks Tick-Borne Dis. 2021;12(5):101766.
   PubMed Web of Science ®Google Scholar
• Tufts DM, Hart TM, Chen GF, et al. Outer surface protein polymorphisms linked to host-spirochete association in Lyme borreliae. Mol Microbiol. 2019;111(4):868–882.
   PubMed Web of Science ®Google Scholar
• Helble JD, McCarthy JE, Hu LT. Interactions between Borrelia burgdorferi and its hosts across the enzootic cycle. Parasite Immunol. 2021;43(5):e12816.
   PubMed Web of Science ®Google Scholar
• O’Bier NS, Hatke AL, Camire AC, et al. Human and veterinary vaccines for Lyme disease. Curr Issues Mol Biol. 2020;42:191–222.
   PubMed Web of Science ®Google Scholar
• Dattwyler RJ, and Gomes-Solecki M. The year that shaped the outcome of the OspA vaccine for human Lyme disease. NPJ Vaccines. 2022;7(1):10.
   PubMed Web of Science ®Google Scholar
• Schwan TG. Temporal regulation of outer surface proteins of the Lyme-disease spirochaete Borrelia burgdorferi. Biochem Soc Trans. 2003;31(Pt 1):108–112.
   PubMedGoogle Scholar
• Schwan TG, Piesman J, Golde WT, et al. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proceedings of the National Academy of Sciences of the United States of America, 92( 7), 2909–2913 (1995).
   Google Scholar
• Hodzic E, Feng S, Freet KJ, et al. Borrelia burgdorferi population kinetics and selected gene expression at the host-vector interface. Infect Immun. 2002;70(7):3382–3388.
   PubMed Web of Science ®Google Scholar
• Yang XF, Pal U, Alani SM, et al. Essential role for OspA/B in the life cycle of the Lyme disease spirochete. J Exp Med. 2004;199(5):641–648.
   PubMed Web of Science ®Google Scholar
• Pal U, de Silva AM, Montgomery RR, et al. Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A. J Clin Invest. 2000;106(4):561–569.
   PubMed Web of Science ®Google Scholar
• Pal U, Yang X, Chen M, et al. OspC facilitates Borrelia burgdorferi invasion of Ixodes scapularis salivary glands. J Clin Invest. 2004;113(2):220–230.
   PubMed Web of Science ®Google Scholar
• Pal U, Montgomery RR, Lusitani D, et al. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. J Iimmunol. 2001;166(12):7398–7403.
   PubMed Web of Science ®Google Scholar
• Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med. 1998;339(4):209–215.
   PubMed Web of Science ®Google Scholar
• Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. recombinant outer-surface protein A Lyme disease vaccine study consortium. N Engl J Med. 1998;339(4):216–222.
   PubMed Web of Science ®Google Scholar
• Gross DM, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science. 1998;281(5377):703–706.
   PubMed Web of Science ®Google Scholar
• Hemmer B, Vergelli M, Gran B, et al. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J Iimmunol. 1998;160(8):3631–3636.
   PubMed Web of Science ®Google Scholar
• Hemmer B, Vergelli M, Pinilla C, et al. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today. 1998;19(4):163–168.
   PubMedGoogle Scholar
• Maier B, Molinger M, Cope AP, et al. Multiple cross-reactive self-ligands for Borrelia burgdorferi-specific HLA-DR4-restricted T cells. Eur J Immunol. 2000;30(2):448–457.
   PubMed Web of Science ®Google Scholar
• Steere AC, Drouin EE, Glickstein LJ. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2011;52(3):s259–265. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America.
   PubMedGoogle Scholar
• Fikrig E, Barthold SW, Kantor FS, et al. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science. 1990;250(4980):553–556.
   PubMed Web of Science ®Google Scholar
• Fikrig E, Telford SR 3rd, Barthold SW, et al. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proceedings of the National Academy of Sciences of the United States of America, 89( 12), 5418–5421 (1992).
   Google Scholar
• de Silva AM, Telford SR 3rd, Brunet LR, et al. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med. 1996;183(1):271–275.
   PubMed Web of Science ®Google Scholar
• Pal U, Li X, Wang T, et al. TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi. Cell. 2004;119(4):457–468.
   PubMed Web of Science ®Google Scholar
• Preac-Mursic V, Wilske B, Patsouris E, et al. Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection. 1992;20(6):342–349.
   PubMed Web of Science ®Google Scholar
• Probert WS, LeFebvre RB. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infection and Immunity. 1994;62(5):1920–1926.
   PubMed Web of Science ®Google Scholar
• Kung F, Kaur S, Smith AA, et al. A Borrelia burgdorferi surface-exposed transmembrane protein lacking detectable immune responses supports pathogen persistence and constitutes a vaccine target. J Infect Dis. 2016;213(11):1786–1795.
   PubMed Web of Science ®Google Scholar
• Kumar M, Yang X, Coleman AS, et al. BBA52 facilitates Borrelia burgdorferi transmission from feeding ticks to murine hosts. J Infect Dis. 2010;201(7):1084–1095.
   PubMed Web of Science ®Google Scholar
• Seshu J, Esteve-Gassent MD, Labandeira-Rey M, et al. Inactivation of the fibronectin-binding adhesin gene bbk32 significantly attenuates the infectivity potential of Borrelia burgdorferi. Mol Microbiol. 2006;59(5):1591–1601.
   PubMed Web of Science ®Google Scholar
• Li X, Liu X, Beck DS, et al. Borrelia burgdorferi lacking BBK32, a fibronectin-binding protein, retains full pathogenicity. Infect Immun. 2006;74(6):3305–3313.
   PubMed Web of Science ®Google Scholar
• Hanson MS, Cassatt DR, Guo BP, et al. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun. 1998;66(5):2143–2153.
   PubMed Web of Science ®Google Scholar
• Shi Y, Xu Q, McShan K, et al. Both decorin-binding proteins A and B are critical for the overall virulence of Borrelia burgdorferi. Infect Immun. 2008;76(3):1239–1246.
   PubMed Web of Science ®Google Scholar
• Shi Y, Xu Q, Seemanapalli SV, et al. The dbpBA locus of Borrelia burgdorferi is not essential for infection of mice. Infect Immun. 2006;74(11):6509–6512.
   PubMed Web of Science ®Google Scholar
• Weening EH, Parveen N, Trzeciakowski JP, et al. Borrelia burgdorferi lacking DbpBA exhibits an early survival defect during experimental infection. Infect Immun. 2008;76(12):5694–5705.
   PubMed Web of Science ®Google Scholar
• Blevins JS, Hagman KE, Norgard MV. Assessment of decorin-binding protein A to the infectivity of Borrelia burgdorferi in the murine models of needle and tick infection. BMC Microbiol. 2008;8(82).
   PubMedGoogle Scholar
• Byram R, Gaultney RA, Floden AM, et al. Borrelia burgdorferi RevA significantly affects pathogenicity and host response in the mouse model of Lyme disease. Infect Immun. 2015;83(9):3675–3683.
   PubMed Web of Science ®Google Scholar
• Floden AM, Gonzalez T, Gaultney RA, et al. Evaluation of RevA, a fibronectin-binding protein of Borrelia burgdorferi, as a potential vaccine candidate for lyme disease. Clin vaccin immunol. 2013;20(6):892–899.
   PubMedGoogle Scholar
• Gomes-Solecki M. Blocking pathogen transmission at the source: reservoir targeted OspA-based vaccines against Borrelia burgdorferi. Front Cell Infect Microbiol. 2014;4:136.
   PubMed Web of Science ®Google Scholar
• Voordouw MJ, Tupper H, Onder O, et al. Reductions in human Lyme disease risk due to the effects of oral vaccination on tick-to-mouse and mouse-to-tick transmission. Vector Borne Zoonotic Dis. 2013;13(4):203–214.
   PubMed Web of Science ®Google Scholar
• Tsao K, Fish D, Galvani AP. Predicted outcomes of vaccinating wildlife to reduce human risk of Lyme disease. Vector Borne Zoonotic Dis. 2012;12(7):544–551.
   PubMed Web of Science ®Google Scholar
• Gomes-Solecki M, Arnaboldi PM, and Backenson PB, et al. Protective immunity and new vaccines for Lyme disease. Clin Infect Dis. 2020;70(8):1768–1773.
   PubMed Web of Science ®Google Scholar
• Embers ME, and Narasimhan S. Vaccination against Lyme disease: past, present, and future. Front Cell Infect Microbiol. 2013;3:1.
   PubMed Web of Science ®Google Scholar
• Meirelles Richer L, Aroso M, Contente-Cuomo T, et al. Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice. Clin Vaccine Immunol. 2011;18(11):1809–1816.
   PubMedGoogle Scholar
• Bhattacharya D, Bensaci M, Luker KE, et al. Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease. Vaccine. 2011;29(44):7818–7825.
   PubMed Web of Science ®Google Scholar
• Kurtenbach K, Dizij A, Voet P, et al. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies. Vaccine. 1997;15(15):1670–1674.
   PubMed Web of Science ®Google Scholar
• Scheckelhoff MR, Telford SR, Hu LT. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine. 2006;24(11):1949–1957.
   PubMed Web of Science ®Google Scholar
• Tsao JI, Wootton JT, Bunikis J, et al. An ecological approach to preventing human infection: vaccinating wild mouse reservoirs intervenes in the Lyme disease cycle. Proceedings of the National Academy of Sciences of the United States of America, 101( 52), 18159–18164 (2004).
   Google Scholar
• Richer LM, Brisson D, Melo R, et al. Reservoir targeted vaccine against Borrelia burgdorferi: a new strategy to prevent Lyme disease transmission. J Infect Dis. 2014;209(12):1972–1980.
   PubMed Web of Science ®Google Scholar
• Grimm D, Tilly K, Byram R, et al. Outer-surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection of mammals. Proceedings of the National Academy of Sciences of the United States of America, 101( 9), 3142–3147 (2004).
   Google Scholar
• Tilly K, Krum JG, Bestor A, et al. Borrelia burgdorferi OspC protein required exclusively in a crucial early stage of mammalian infection. Infect Immun. 2006;74(6):3554–3564.
   PubMed Web of Science ®Google Scholar
• Ramamoorthi N, Narasimhan S, Pal U, et al. The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature. 2005;436(7050):573–577.
   PubMed Web of Science ®Google Scholar
• Caine JA, Lin YP, Kessler JR, et al. Borrelia burgdorferi outer surface protein C (OspC) binds complement component C4b and confers bloodstream survival. Cell Microbiol. 2017;19:e12786.
   Web of Science ®Google Scholar
• Lin YP, Tan X, Caine JA, et al. Strain-specific joint invasion and colonization by Lyme disease spirochetes is promoted by outer surface protein C. PLoS Pathog. 2020;16(5):e1008516.
   PubMed Web of Science ®Google Scholar
• Lagal V, Portnoi D, Faure G, et al. Borrelia burgdorferi sensu stricto invasiveness is correlated with OspC-plasminogen affinity. Microbes Infect. 2006;8(3):645–652.
   PubMed Web of Science ®Google Scholar
• Bockenstedt LK, Hodzic E, Feng S, et al. Borrelia burgdorferi strain-specific OspC-mediated immunity in mice. Infect Immun. 1997;65(11):4661–4667.
   PubMed Web of Science ®Google Scholar
• Gilmore RD Jr., Piesman J, Moore RN. Inhibition of Borrelia burgdorferi migration from the midgut to the salivary glands following feeding by ticks on OspC-immunized mice. Infect Immun. 2000;68(1):411–414.
   PubMed Web of Science ®Google Scholar
• Mbow ML, Gilmore RD Jr., Titus RG. An OspC-specific monoclonal antibody passively protects mice from tick-transmitted infection by Borrelia burgdorferi B31. Infect Immun. 1999;67(10):5470–5472.
   PubMed Web of Science ®Google Scholar
• Wilske B, Preac-Mursic V, Jauris S, et al. Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi. Infect Immun. 1993;61(5):2182–2191.
   PubMed Web of Science ®Google Scholar
• Earnhart CG, Buckles EL, Dumler JS, et al. Demonstration of OspC type diversity in invasive human lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response. Infect Immun. 2005;73(12):7869–7877.
   PubMed Web of Science ®Google Scholar
• Reis ES, Mastellos DC, Hajishengallis G, et al. New insights into the immune functions of complement. Nat Rev Immunol. 2019;19(8):503–516.
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Hallstrom T, Riesbeck K. Human complement control and complement evasion by pathogenic microbes–tipping the balance. Mol Immunol. 2013;56(3):152–160.
   PubMed Web of Science ®Google Scholar
• Blom AM. The role of complement inhibitors beyond controlling inflammation. J Intern Med. 2017;282(2):116–128.
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9(10):729–740.
   PubMed Web of Science ®Google Scholar
• Skare JT, Garcia BL. Complement evasion by Lyme disease spirochetes. Trends Microbiol. 2020;28(11):889–899.
   PubMed Web of Science ®Google Scholar
• Lin YP, Diuk-Wasser MA, Stevenson B, et al. Complement evasion contributes to Lyme Borreliae-host associations. Trends Parasitol. 2020;36(7):634–645.
   PubMed Web of Science ®Google Scholar
• Dulipati V, Meri S, Panelius J. Complement evasion strategies of Borrelia burgdorferi sensu lato. FEBS Lett. 2020;594(16):2645–2656.
   PubMed Web of Science ®Google Scholar
• Hartmann K, Corvey C, Skerka C, et al. Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1. Mol Microbiol. 2006;61(5):1220–1236.
   PubMed Web of Science ®Google Scholar
• Lin YP, Frye AM, Nowak TA, et al. New Insights Into CRASP-mediated complement evasion in the Lyme disease enzootic cycle. Front Cell Infect Microbiol. 2020;10:1.
   PubMed Web of Science ®Google Scholar
• Bykowski T, Woodman ME, Cooley AE, et al. Coordinated expression of Borrelia burgdorferi complement regulator-acquiring surface proteins during the Lyme disease spirochete’s mammal-tick infection cycle. Infect Immun. 2007;75(9):4227–4236.
   PubMed Web of Science ®Google Scholar
• Marcinkiewicz AL, Dupuis AP, Zamba-Campero M, et al. Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hosts. Cell Microbiol. 2019;21(2):e12998.
   PubMed Web of Science ®Google Scholar
• Kraiczy P, Seling A, Brissette CA, et al. Borrelia burgdorferi complement regulator-acquiring surface protein 2 (CspZ) as a serological marker of human Lyme disease. Clin Vaccin Immunol. 2008;15(3):484–491.
   PubMedGoogle Scholar
• Rogers EA, Abdunnur SV, McDowell JV, et al. Comparative analysis of the properties and ligand binding characteristics of CspZ, a factor H binding protein, derived from Borrelia burgdorferi isolates of human origin. Infect Immun. 2009;77(10):4396–4405.
   PubMed Web of Science ®Google Scholar
• Rogers EA, Marconi RT. Delineation of species-specific binding properties of the CspZ protein (BBH06) of Lyme disease spirochetes: evidence for new contributions to the pathogenesis of Borrelia spp. Infect Immun. 2007;75(11):5272–5281.
   PubMed Web of Science ®Google Scholar
• Coleman AS, Yang X, Kumar M, et al. Borrelia burgdorferi complement regulator-acquiring surface protein 2 does not contribute to complement resistance or host infectivity. PloS one. 2008;3(8):3010e.
   PubMed Web of Science ®Google Scholar
• Kumar M, Kaur S, Kariu T, et al. Borrelia burgdorferi BBA52 is a potential target for transmission blocking Lyme disease vaccine. Vaccine. 2011;29(48):9012–9019.
   PubMed Web of Science ®Google Scholar
• Klouwens MJ, Trentelman JJ, Ersoz JI, et al. Investigating BB0405 as a novel Borrelia afzelii vaccination candidate in Lyme borreliosis. Sci Rep. 2021;11(1):4775.
   PubMed Web of Science ®Google Scholar
• Singh P, Verma D, Backstedt BT, et al. Borrelia burgdorferi BBI39 paralogs, targets of protective immunity, reduce pathogen persistence either in hosts or in the vector. J Infect Dis. 2017;215(6):1000–1009.
   PubMed Web of Science ®Google Scholar
• Brandt KS, Gilmore RD. Immunization of mice with Borrelia burgdorferi lp54 gene encoded recombinant proteins does not provide protection against tick transmitted infectious challenge. Vaccine. 2017;35(40):5310–5313.
   PubMed Web of Science ®Google Scholar
• Brandt KS, Patton TG, Allard AS, et al. Evaluation of the Borrelia burgdorferi BBA64 protein as a protective immunogen in mice. Clin vaccin immunol. 2014;21(4):526–533.
   PubMedGoogle Scholar
• Gilmore RD Jr., Kappel KJ, Dolan MC, et al. Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect Immun. 1996;64(6):2234–2239.
   PubMed Web of Science ®Google Scholar
• Brown EL, Kim JH, Reisenbichler ES, et al. Multicomponent Lyme vaccine: three is not a crowd. Vaccine. 2005;23(28):3687–3696.
   PubMed Web of Science ®Google Scholar
• Hagman KE, Yang X, Wikel SK, et al. Decorin-binding protein A (DbpA) of Borrelia burgdorferi is not protective when immunized mice are challenged via tick infestation and correlates with the lack of DbpA expression by B. burgdorferi in ticks. Infect Immun. 2000;68(8):4759–4764.
   PubMed Web of Science ®Google Scholar
• Small CM, Ajithdoss DK, Rodrigues Hoffmann A, et al. Immunization with a Borrelia burgdorferi BB0172-derived peptide protects mice against lyme disease. PloS one. 2014;9(2):e88245.
   PubMed Web of Science ®Google Scholar
• Eisen L. Vector competence studies with hard ticks and Borrelia burgdorferi sensu lato spirochetes: a review. Ticks Tick-Borne Dis. 2020;11(3):101359.
   PubMed Web of Science ®Google Scholar
• Schuijt TJ, Hovius JW, van der Poll T, et al. Lyme borreliosis vaccination: the facts, the challenge, the future. Trends Parasitol. 2011;27(1):40–47.
   PubMed Web of Science ®Google Scholar
• Rego ROM, Trentelman JJA, and Anguita J, et al. Counterattacking the tick bite: towards a rational design of anti-tick vaccines targeting pathogen transmission. Parasit Vectors. 2019;12(1):229.
   PubMedGoogle Scholar
• Koci J, Bista S, Chirania P, et al. Antibodies against EGF-like domains in Ixodes scapularis BM86 orthologs impact tick feeding and survival of Borrelia burgdorferi. Sci Rep. 2021;11(1):6095.
   PubMed Web of Science ®Google Scholar
• Dai J, Wang P, Adusumilli S, et al. Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. Cell Host Amp; Microbe. 2009;6(5):482–492.
   PubMed Web of Science ®Google Scholar
• Gomes-Solecki M, Arnaboldi PM, Backenson PB, et al. Protective immunity and new vaccines for Lyme disease. Clin Infect Dis. 2019;68:1052–1057.
   PubMedGoogle Scholar
• Sprong H, Trentelman J, Seemann I, et al. ANTIDotE: anti-tick vaccines to prevent tick-borne diseases in Europe. Parasit Vectors. 2014;7:77.
   PubMed Web of Science ®Google Scholar
• Sajid A, Matias J, Arora G, et al. mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent. Sci Transl Med. 2021;13(620):eabj9827.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Dolan MC, Sackal CA, et al. Immunization with adenoviral-vectored tick salivary gland proteins (SALPs) in a murine model of Lyme borreliosis. TicksTick-Borne Dis. 2013;4(1–2):160–163.
   PubMed Web of Science ®Google Scholar
• Dai J, Narasimhan S, Zhang L, et al. Tick histamine release factor is critical for Ixodes scapularis engorgement and transmission of the lyme disease agent. PLoS Pathogens. 2010;6(11):e1001205.
   PubMed Web of Science ®Google Scholar
• Klouwens MJ, Trentelman JJA, Wagemakers A, et al. Tick-tattoo: DNA vaccination Against B. burgdorferi or Ixodes scapularis tick proteins. Front Immunol. 2021;12:615011.
   PubMed Web of Science ®Google Scholar
• Narasimhan S, Kurokawa C, DeBlasio M, et al. Acquired tick resistance: the trail is hot. Parasite Immunol. 2021;43(5):e12808.
   PubMed Web of Science ®Google Scholar
• Kitsou C, Fikrig E, Pal U. Tick host immunity: vector immunomodulation and acquired tick resistance. Trends Immunol. 2021;42(7):554–574.
   PubMed Web of Science ®Google Scholar
• Lynn GE, Diktas H, DePonte K, et al. Naturally acquired resistance to Ixodes scapularis elicits partial immunity against other tick vectors in a laboratory host. Am J Trop Med Hyg. 2021;104(1):175–183.
   PubMed Web of Science ®Google Scholar
• Cerny J, Lynn G, DePonte K, et al. Fractionation of tick saliva reveals proteins associated with the development of acquired resistance to Ixodes scapularis. Vaccine. 2020;38(51):8121–8129.
   PubMed Web of Science ®Google Scholar
• Kurokawa C, Narasimhan S, Vidyarthi A, et al. Repeat tick exposure elicits distinct immune responses in Guinea pigs and mice. Ticks Tick-Borne Dis. 2020;11(6):101529.
   PubMed Web of Science ®Google Scholar
• Matias J, Kurokawa C, Sajid A, et al. Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies. Vaccine. 2021;39(52):7661–7668.
   PubMed Web of Science ®Google Scholar
• de la Fuente J, Estrada-Pena A, Contreras M. Modeling tick vaccines: a key tool to improve protection efficacy. Expert Rev Vaccines. 2020;19(3):217–225.
   PubMed Web of Science ®Google Scholar
• Caradonna TM, and Schmidt AG. Protein engineering strategies for rational immunogen design. NPJ Vaccines. 2021;6(1):154.
   PubMed Web of Science ®Google Scholar
• Angeletti D, Yewdell JW. Understanding and manipulating viral immunity: antibody immunodominance enters center stage. Trends Immunol. 2018;39(7):549–561.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Nojima T, Kuraoka M, et al. Germinal center entry not selection of B cells is controlled by peptide-MHCII complex density. Nat Commun. 2018;9(1):928.
   PubMedGoogle Scholar
• Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol. 1997;15:235–270.
   PubMed Web of Science ®Google Scholar
• Tornesello AL, Tagliamonte M, Buonaguro FM, et al. Virus-like particles as preventive and therapeutic cancer vaccines. Vaccines (Basel). 2022;10(2).
   PubMed Web of Science ®Google Scholar
• Ramos TI, Villacis-Aguirre CA, Lopez-Aguilar KV, et al. The hitchhiker’s guide to human therapeutic nanoparticle development. Pharmaceutics. 2022;14(2):247.
   PubMedGoogle Scholar
• Sriwidodo UAK, Wathoni N, Zothantluanga JH, et al. Liposome-polymer complex for drug delivery system and vaccine stabilization. Heliyon. 2022;8(2):e08934.
   PubMed Web of Science ®Google Scholar
• Kolb P, Wallich R, Nassal M. Whole-chain tick saliva proteins presented on hepatitis B virus capsid-like particles induce high-titered antibodies with neutralizing potential. PloS one. 2015;10(9):e0136180.
   PubMed Web of Science ®Google Scholar
• Federizon J, Frye A, Huang WC, et al. Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes. Vaccine. 2020;38(4):942–950.
   PubMed Web of Science ®Google Scholar
• Krupka M, Masek J, Bartheldyova E, et al. Enhancement of immune response towards non-lipidized Borrelia burgdorferi recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP. J Control Release. 2012;160(2):374–381.
   PubMed Web of Science ®Google Scholar
• Kamp HD, Swanson KA, Wei RR, et al. Design of a broadly reactive Lyme disease vaccine. NPJ Vaccines. 2020;5(1):33.
   PubMed Web of Science ®Google Scholar
• Marcinkiewicz AL, Lieknina I, Kotelovica S, et al. Eliminating factor H-binding activity of Borrelia burgdorferi CspZ combined with virus-like particle conjugation enhances its efficacy as a Lyme disease vaccine. Front Immunol. 2018;9:181.
   PubMed Web of Science ®Google Scholar
• Kanekiyo M, Wei CJ, Yassine HM, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013;499(7456):102–106.
   PubMed Web of Science ®Google Scholar
• Darricarrere N, Pougatcheva S, Duan X, et al. Development of a Pan-H1 influenza vaccine. J Virol. 2018;92(22).
   PubMed Web of Science ®Google Scholar
• Kuraoka M, Schmidt AG, Nojima T, et al. Complex antigens drive permissive clonal selection in germinal centers. Immunity. 2016;44(3):542–552.
   PubMed Web of Science ®Google Scholar
• Finney J, Yeh CH, Kelsoe G, et al. Germinal center responses to complex antigens. Immunol Rev. 2018;284(1):42–50.
   PubMed Web of Science ®Google Scholar
• Willett TA, Meyer AL, Brown EL, et al. An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proceedings of the National Academy of Sciences of the United States of America, 101( 5), 1303–1308 (2004).
   Google Scholar
• Ding W, Huang X, Yang X, et al. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. J Mol Biol. 2000;302(5):1153–1164.
   PubMed Web of Science ®Google Scholar
• Schubach WH, Mudri S, Dattwyler RJ, et al. Mapping antibody-binding domains of the major outer surface membrane protein (OspA) of Borrelia burgdorferi. Infect Immun. 1991;59(6):1911–1915.
   PubMed Web of Science ®Google Scholar
• Golde WT, Piesman J, Dolan MC, et al. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun. 1997;65(3):882–889.
   PubMed Web of Science ®Google Scholar
• Koide S, Yang X, Huang X, et al. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J Mol Biol. 2005;350(2):290–299.
   PubMed Web of Science ®Google Scholar
• Wilske B, Preac-Mursic V, Gobel UB, et al. An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J Clin Microbiol. 1993;31(2):340–350.
   PubMed Web of Science ®Google Scholar
• Livey I, O’Rourke M, Traweger A, et al. A new approach to a Lyme disease vaccine. Clin Infect Dis. 2011;52(3):s266–270.
   PubMedGoogle Scholar
• Wressnigg N, Pollabauer EM, Aichinger G, et al. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis. 2013;13(8):680–689.
   PubMed Web of Science ®Google Scholar
• Wressnigg N, Barrett PN, Pollabauer EM, et al. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato. Clin vaccin immunol. 2014;21(11):1490–1499.
   PubMed Web of Science ®Google Scholar
• Comstedt P, Hanner M, Schuler W, et al. Design and development of a novel vaccine for protection against Lyme borreliosis. PloS one. 2014;9(11):e113294.
   PubMed Web of Science ®Google Scholar
• Comstedt P, Schuler W, Meinke A, et al. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PloS one. 2017;12(9):e0184357.
   PubMed Web of Science ®Google Scholar
• Comstedt P, Hanner M, Schuler W, et al. Characterization and optimization of a novel vaccine for protection against Lyme borreliosis. Vaccine. 2015;33(44):5982–5988.
   PubMed Web of Science ®Google Scholar
• Valneva and Pfizer report further positive phase 2 data for Lyme disease vaccine candidate. (Ed.^(Eds). 2022.
   Google Scholar
• Bajic G, Maron MJ, Caradonna TM, et al. Structure-guided molecular grafting of a complex broadly neutralizing viral epitope. ACS Infect Dis. 2020;6(5):1182–1191.
   PubMed Web of Science ®Google Scholar
• Nayak A, Schuler W, Seidel S, et al. Broadly protective multivalent OspA vaccine against lyme borreliosis, developed based on surface shaping of the C-terminal fragment. Infect Immun. 2020;88(4).
   PubMed Web of Science ®Google Scholar
• Buckles EL, Earnhart CG, Marconi RT. Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine development. Clin vaccin immunol. 2006;13(10):1162–1165.
   PubMedGoogle Scholar
• Earnhart CG, Buckles EL, Marconi RT. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine. 2007;25(3):466–480.
   PubMed Web of Science ®Google Scholar
• Earnhart CG, Marconi RT. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences. Hum Vaccines. 2007;3(6):281–289.
   PubMed Web of Science ®Google Scholar
• Oliver LD Jr., Earnhart CG, Virginia-Rhodes D, et al. Antibody profiling of canine IgG responses to the OspC protein of the Lyme disease spirochetes supports a multivalent approach in vaccine and diagnostic assay development. Vet J. 2016;218:27–33.
   PubMed Web of Science ®Google Scholar
• Earnhart CG, Marconi RT. Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens. Vaccine. 2007;25(17):3419–3427.
   PubMed Web of Science ®Google Scholar
• Izac JR, O’Bier NS, Oliver LD Jr., et al. Development and optimization of OspC chimeritope vaccinogens for Lyme disease. Vaccine. 2020;38(8):1915–1924.
   PubMed Web of Science ®Google Scholar
• Marconi RT, Garcia-Tapia D, Hoevers J, et al. VANGUARD(R)crLyme: a next generation Lyme disease vaccine that prevents B. burgdorferi infection in dogs. Vaccine X. 2020; 6: 100079.
   PubMedGoogle Scholar
• Ringe RP, Pugach P, Cottrell CA, et al. Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes. J Virol. 2019;93(4.
   PubMed Web of Science ®Google Scholar
• Dubrovskaya V, Tran K, Ozorowski G, et al. Vaccination with glycan-modified HIV NFL envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability. Immunity. 2019;51(5):915–929 e917.
   PubMed Web of Science ®Google Scholar
• Liu WC, Jan JT, Huang YJ, et al. Unmasking stem-specific neutralizing epitopes by abolishing N-linked glycosylation sites of influenza virus hemagglutinin proteins for vaccine design. J Virol. 2016;90(19):8496–8508.
   PubMed Web of Science ®Google Scholar
• Marcinkiewicz AL, Lieknina I, Yang X, et al. The factor H-binding site of CspZ as a protective target against multistrain, tick-transmitted lyme disease. Infect Immun. 2020;88(5).
   PubMed Web of Science ®Google Scholar
• Ferreira VP, Pangburn MK, Cortes C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol. 2010;47(13):2187–2197.
   PubMed Web of Science ®Google Scholar
• Bockenstedt LK, Fikrig E, Barthold SW, et al. Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice. J Iimmunol. 1993;151(2):900–906.
   PubMed Web of Science ®Google Scholar
• Dunn JJ, Lade BN, Barbour AG. Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA. Protein Expr Purif. 1990;1(2):159–168.
   PubMedGoogle Scholar
• Amet N, Lee HF, Shen WC. Insertion of the designed helical linker led to increased expression of tf-based fusion proteins. Pharm Res. 2009;26(3):523–528.
   PubMed Web of Science ®Google Scholar
• Zhao HL, Yao XQ, Xue C, et al. Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering. Protein Expr Purif. 2008;61(1):73–77.
   PubMed Web of Science ®Google Scholar
• Bai Y, Shen WC. Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm Res. 2006;23(9):2116–2121.
   PubMed Web of Science ®Google Scholar
• Crasto CJ, Feng JA. LINKER: a program to generate linker sequences for fusion proteins. Protein Eng. 2000;13(5):309–312.
   PubMedGoogle Scholar
• Reddy Chichili VP, Kumar V, Sivaraman J. Linkers in the structural biology of protein-protein interactions. Protein Sci. 2013;22(2):153–167.
   PubMed Web of Science ®Google Scholar
• Chen X, Zaro JL, Shen WC. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013;65(10):1357–1369.
   PubMed Web of Science ®Google Scholar
• Radford SE, Laue ED, Perham RN, et al. Segmental structure and protein domains in the pyruvate dehydrogenase multienzyme complex of Escherichia coli. Genetic reconstruction in vitro and 1H-n.m.r. spectroscopy. Biochem J. 1987;247(3):641–649.
   PubMed Web of Science ®Google Scholar
• Lubkowski J, Hennecke F, Pluckthun A, et al. Filamentous phage infection: crystal structure of g3p in complex with its coreceptor, the C-terminal domain of TolA. Structure. 1999;7(6):711–722.
   PubMed Web of Science ®Google Scholar
• Nyon MP, Du L, Tseng CK, et al. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018;36(14):1853–1862.
   PubMed Web of Science ®Google Scholar
• Duivelshof BL, Murisier A, Camperi J, et al. Therapeutic Fc-fusion proteins: current analytical strategies. J Sep Sci. 2021;44(1):35–62.
   PubMed Web of Science ®Google Scholar
• Sun S, He L, Zhao Z, et al. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice. Cell Mol Immunol. 2021;18(4):1070–1073.
   PubMed Web of Science ®Google Scholar
• Lu L, Palaniyandi S, Zeng R, et al. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol. 2011;85(20):10542–10553.
   PubMed Web of Science ®Google Scholar
• Vizcarra CL, Mayo SL. Electrostatics in computational protein design. Curr Opin Chem Biol. 2005;9(6):622–626.
   PubMed Web of Science ®Google Scholar
• Wunderlich M, Schmid FX. The correlation between protein stability and dipole moment: a critical test. Protein Eng Des Sel. 2006;19(8):355–358.
   PubMed Web of Science ®Google Scholar
• Seid CA, Jones KM, Pollet J, et al. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017;13(3):621–633.
   PubMed Web of Science ®Google Scholar
• Chen WH, Wei J, Kundu RT, et al. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim Biophys Acta Gen Subj. 2021;1865(6):129893.
   PubMed Web of Science ®Google Scholar
• Margos G, Vollmer SA, Cornet M, et al. A new Borrelia species defined by multilocus sequence analysis of housekeeping genes. Appl Environ Microbiol. 2009;75(16):5410–5416.
   PubMed Web of Science ®Google Scholar
• Pritt BS, Mead PS, Johnson DKH, et al. Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study. Lancet Infect Dis. 2016;16(5):556–564.
   PubMed Web of Science ®Google Scholar
• Binetruy F, Garnier S, Boulanger N, et al. A novel Borrelia species, intermediate between Lyme disease and relapsing fever groups, in neotropical passerine-associated ticks. Sci Rep. 2020;10(1):10596.
   PubMed Web of Science ®Google Scholar
• Shaffer L. Inner workings: Lyme disease vaccines face familiar challenges, both societal and scientific. Proceedings of the National Academy of Sciences of the United States of America, 116( 39), 19214–19217 (2019).
   Google Scholar